Another sign of the changing environment in the funding of […]
Health Economia Life-Sciences Investment Series October 2022
Successfully investing in early life science assets, such as medical device projects, diagnostics, digital therapeutics or drug therapies, requires conducting thorough scientific due diligence, monitoring the development plan execution, and implementing a development risk assessment & mitigation plan.
Besides the challenging environment, we observed that this era is appropriate to successfully invest in Life Science assets. After interacting with several Biotech founders, we consistently observed that they need the investors' advice and network, as much as the funds.
On 21 Sept 2022, the BIDMC team published the results […]
Earlier this week, the US-FDA announced the issue of an […]
A very nice story, hopefully that will end up as […]
EMA is moving forward with Nitrosamines. After a risk assessment […]